BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion [Yahoo! Finance]
BeOne Medicines (ONC) had its price target raised by Truist Financial Corporation from $400.00 to $412.00. They now have a "buy" rating on the stock.
BeOne Medicines (ONC) had its price target raised by Guggenheim from $400.00 to $410.00. They now have a "buy" rating on the stock.
BeOne Medicines (ONC) had its price target raised by Barclays PLC from $394.00 to $405.00. They now have an "overweight" rating on the stock.
BeOne Medicines (ONC) had its "outperform" rating reaffirmed by Royal Bank Of Canada.